Hennion & Walsh Asset Management Inc. Increases Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Hennion & Walsh Asset Management Inc. increased its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 60.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 66,306 shares of the specialty pharmaceutical company’s stock after buying an additional 25,004 shares during the period. Hennion & Walsh Asset Management Inc. owned about 0.12% of Supernus Pharmaceuticals worth $2,398,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Barclays PLC increased its position in shares of Supernus Pharmaceuticals by 88.3% in the 3rd quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company’s stock valued at $3,393,000 after purchasing an additional 51,005 shares during the last quarter. Segall Bryant & Hamill LLC purchased a new position in Supernus Pharmaceuticals in the third quarter valued at $791,000. Geode Capital Management LLC raised its stake in Supernus Pharmaceuticals by 5.3% in the third quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock valued at $46,218,000 after buying an additional 74,438 shares in the last quarter. Franklin Resources Inc. lifted its holdings in Supernus Pharmaceuticals by 7.6% during the 3rd quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company’s stock worth $987,000 after buying an additional 2,121 shares during the last quarter. Finally, Bank of Montreal Can boosted its position in shares of Supernus Pharmaceuticals by 1,508.0% during the 2nd quarter. Bank of Montreal Can now owns 116,322 shares of the specialty pharmaceutical company’s stock worth $3,287,000 after acquiring an additional 109,088 shares in the last quarter.

Supernus Pharmaceuticals Stock Down 0.3 %

SUPN opened at $37.74 on Friday. The firm has a market cap of $2.08 billion, a price-to-earnings ratio of 35.27 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a 52 week low of $25.53 and a 52 week high of $39.37. The business’s 50 day moving average is $36.67 and its two-hundred day moving average is $33.65.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.25. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The firm had revenue of $175.70 million during the quarter, compared to analysts’ expectations of $157.35 million. During the same quarter in the prior year, the business earned ($0.29) EPS. Supernus Pharmaceuticals’s quarterly revenue was up 14.2% compared to the same quarter last year. Equities analysts expect that Supernus Pharmaceuticals, Inc. will post 2.37 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Georges Gemayel sold 14,213 shares of the stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $36.62, for a total transaction of $520,480.06. Following the completion of the transaction, the director now directly owns 13,315 shares of the company’s stock, valued at approximately $487,595.30. This represents a 51.63 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Frank Mottola sold 15,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $36.98, for a total value of $554,700.00. Following the completion of the sale, the senior vice president now owns 8,200 shares in the company, valued at approximately $303,236. This trade represents a 64.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 154,213 shares of company stock valued at $5,660,180 over the last three months. 9.30% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

SUPN has been the topic of several research analyst reports. Piper Sandler reissued a “neutral” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Cowen reissued a “buy” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Finally, Cantor Fitzgerald began coverage on shares of Supernus Pharmaceuticals in a report on Monday, January 6th. They issued an “overweight” rating and a $57.00 target price for the company.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.